Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma
Phase 1b/2 study shows 84% overall response and encouraging safety in patients with relapsed/refractory multiple myeloma.
Key Points
The study aims to evaluate the safety and efficacy of sonrotoclax combined with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma patients with t(11;14).
Phase 1b/2 study evaluating sonrotoclax, carfilzomib, and dexamethasone in MM with t(11;14).
Patients received 320 or 640 mg oral sonrotoclax plus carfilzomib and dexamethasone until disease progression or unacceptable toxicity.
Study endpoints included safety assessments and overall response rate per International Myeloma Working Group guidelines.
Out of 20 patients, 84% achieved an overall response rate, including 32% with complete response.
Median follow-up was 7.3 months, with the median age of patients at 65 years.
The most common treatment-emergent adverse events were insomnia, fatigue, and nausea.